A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)

Inclusion Criteria: * Histologically or cytologically confirmed diagnosis of unresectable Stage IIIb not amenable to treatment with combined modality chemoradiation (advanced) or Stage IV (metastatic) NSCLC * Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2 * Measurable disease * Adequate recovery from most recent systemic or local treatment for cancer * Adequate organ function * Life expectancy greater than or equal to (\>/=) 12 weeks * For female participants of childbearing potential and male participants, willingness to use acceptable methods of contraception Exclusion Criteria: * Inability to swallow oral medication * Women who are pregnant or lactating * Symptomatic, untreated CNS metastases * History of malignancy other than NSCLC within 5 years prior to screening with the exception of malignancies with negligible risk of metastasis or death * Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or greater), myocardial infarction, or cerebrovascular accident within 3 months prior to randomization, unstable arrhythmias, or unstable angina * Known active or uncontrolled human immunodeficiency virus (HIV) infection * Either a concurrent condition or history of a prior condition that places the patient at unacceptable risk if he/she were treated with the study drug or confounds the ability to interpret data from the study * Inability to comply with other requirements of the protocol